The combined company has annual pro forma revenues of more than $23 billion anticipated in 2015. Additionally, it intends to invest approximately $1.7 billion in research and development in 2015.
“The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model — Growth Pharma,” said Brent Saunders, CEO and president of Actavis.
More articles on GI/endoscopy:
AGA: Young investigators award deadline extended
4 new GI centers & partnerships
New HCV pills drive U.S. drug spending up 13.1%
